Newark-based BioCentriq, a cell and gene therapy manufacturing company, said Wednesday that Jackie Veivia-Panter has been named its new chief quality and compliance officer.
Veivia-Panter has 30 years of experience in the pharmaceutical and cell therapy industry with specialized expertise in quality management. Her skills include designing and delivering effective and compliant solutions, processes and organizational models. Throughout her career, she has managed site quality and research & development quality and has held global roles in training, regulatory intelligence and matrix organization management.
“BioCentriq is at the forefront of developing and manufacturing cell and gene therapies, and I’m grateful for the opportunity to help usher it into its next era as a leading CDMO,” Veivia-Panter said.
As the former vice president, global head of quality at Minaris Regenerative Medicine, which included Europe, Asia and North America, Veivia-Panter was responsible for the oversight of all quality-related functions, such as quality systems, quality control, regulatory and quality site heads.
Veivia-Panter was also in charge with creating and implementing a global quality strategy. Prior to that, she was the senior director of global quality systems and compliance at Legend Biotech, where she developed and deployed a global good practice quality system and compliance strategy consisting of policy, process, SOP development and electronic system implementation.
“We’re thrilled to welcome Jackie to the BioCentriq team,” BioCentriq’s CEO, Haro Hartounian, said. “Her deep knowledge of quality management and compliance standards, specifically within the cell and gene therapy industry, will be an incredible asset.”
